Larimar Therapeutics (LRMR) Net Income towards Common Stockholders: 2012-2019
Historic Net Income towards Common Stockholders for Larimar Therapeutics (LRMR) over the last 8 years, with Dec 2019 value amounting to -$45.4 million.
- Larimar Therapeutics' Net Income towards Common Stockholders rose 72.55% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.68%. This contributed to the annual value of -$45.4 million for FY2019, which is 25.68% up from last year.
- Latest data reveals that Larimar Therapeutics reported Net Income towards Common Stockholders of -$45.4 million as of FY2019, which was up 25.68% from -$61.1 million recorded in FY2018.
- In the past 5 years, Larimar Therapeutics' Net Income towards Common Stockholders registered a high of -$45.4 million during FY2019, and its lowest value of -$74.3 million during FY2015.
- Its 3-year average for Net Income towards Common Stockholders is -$52.9 million, with a median of -$52.2 million in 2017.
- In the last 5 years, Larimar Therapeutics' Net Income towards Common Stockholders crashed by 103.13% in 2015 and then climbed by 25.68% in 2019.
- Over the past 5 years, Larimar Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$74.3 million in 2015, then climbed by 22.09% to -$57.9 million in 2016, then rose by 9.87% to -$52.2 million in 2017, then decreased by 17.18% to -$61.1 million in 2018, then grew by 25.68% to -$45.4 million in 2019.